Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics, Inc. experienced several stock events in the past six months. These include the release of financial results for Q1, Q2 and Q3 2025, presentations at the AACR-NCI-EORTC International Conference, and analyst ratings adjustments from Oppenheimer, Weiss Ratings, HC Wainwright, and Wall Street Zen. The stock experienced a significant decline of 64.91% over the past year, but showed an increase of 10.14% in the past month.

As a clinical-stage biopharmaceutical company without marketed products, Acrivon Therapeutics, Inc. does not have traditional demand seasonality. However, there is observed "Monthly Seasonality" in its stock performance, with January historically showing the highest probability of a positive return and May the lowest. This seasonality relates to stock market trends rather than product demand.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology medicines, utilizing its AP3 platform to identify patients likely to respond to specific treatments. Its major product candidates include ACR-368, a CHK1 and CHK2 inhibitor in Phase 2 trials for various cancers, with an OncoSignature test to predict patient response; ACR-2316, a dual WEE1 and PKMYT1 inhibitor in Phase 1 trial; and the AP3 platform itself, enabling the creation of drug-specific companion diagnostics.

Acrivon Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The company's operations are primarily based in the US, with no explicit details available regarding international operations or global market reach beyond its US base for clinical development.

Acrivon Therapeutics generally holds a "Moderate Buy" consensus rating from analysts, with individual opinions ranging from "Strong Buy" to "Sell." The company has seen positive community sentiment, particularly around its potential resilience and innovative drug development approach, contributing to recent stock price increases. No specific events have negatively impacted its brand reputation beyond the inherent risks of clinical-stage biopharmaceutical development.

Acrivon Therapeutics, Inc. has a mix of institutional, insider, and retail investors. Institutional investors own approximately 38.70% to 41.04% of the company's stock, while insiders hold around 44.65%. Major institutional owners include Ra Capital Management, L.P., Sands Capital Ventures, LLC / Sands Capital Alternatives, Llc, Citadel Advisors Llc, Wellington Management Group Llp, UBS Group AG, Vanguard Group Inc, Renaissance Technologies Llc, Acorn Capital Advisors, Llc and BlackRock, Inc. Chione Ltd is a significant individual shareholder, owning 12.20% of the company's shares.